10x Genomics, Inc. Cash Flow Statement
TXG / Health Care|9 years of annual SEC 10-K data (FY2017-FY2025)
Covers operating cash flow, capital expenditures, free cash flow, share buybacks, and dividends paid across 9 fiscal years. All figures from audited SEC 10-K filings.
10x Genomics, Inc. generated $136M in operating cash flow and $130M in free cash flow in FY2025. Free cash flow margin was 20.2% of revenue.
Based on SEC 10-K filings.
Key Data Points
- Altman Z-Score 0.94 (distress zone, below 1.8 threshold)
- Negative profit margin: -29.9%
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|
| Net Income | -$43.5M | -$182.6M | -$255.1M | -$166.0M | -$58.2M | -$542.7M | -$31.3M | -$112.5M | -$18.8M |
| Depreciation & Amortization | $36.2M | $35.9M | $35.5M | $25.4M | $21.1M | $14.0M | $7.1M | $3.9M | $4.3M |
| Operating Cash Flow | $136.1M | $6.7M | -$15.2M | -$33.6M | -$21.4M | -$217.9M | $34.6M | -$76.4M | -$10.7M |
| Capital Expenditures | $5.9M | $12.4M | $48.6M | $131.7M | $101.3M | $36.7M | $42.7M | $6.3M | $3.8M |
| Free Cash Flow | $130.1M | -$5.7M | -$63.8M | -$165.3M | -$122.7M | -$254.6M | -$8.1M | -$82.7M | -$14.5M |
| Share Buybacks | - | - | - | - | - | - | - | - | $80.0K |
| FCF Margin | 20.2% | -0.9% | -10.3% | -32.0% | -25.0% | -85.2% | -15.2% | - | -20.3% |